Date:11/8/2012

y's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and foreign regulatory agencies; dependence on key customers and sole source suppliers; the company's ability to protect intellectual property rights with respect to its products; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; and potential restrictions on the company's ability and flexibility to pursue future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and future filings and reports by the company, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.    JAZZ PHARMACEUTICALS PLC  CONDENSED CONSOLIDATED STATEMENTS OF INCOME  (In thousands, except per share amounts)  (Unaudited) Three Months Ended September 30,Nine Months Ended September 30,2012201120122011 Revenues:  Product sales, net 

$ 174,130$ 72,216$ 398,585$ 185,583 Royalties and contract revenues 

1,3851,0773,6913,158 Total revenues 

175,51573,293402,276188,741 Operating expenses:  Cost of product sales 

32,6293,90152,66210,080 Selling, general and administrative 

60,92430,547162,50572,552&#
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Isis Pharmaceuticals To Present At The 2012 Credit Suisse Healthcare Conference
4. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
5. Genoa Pharmaceuticals announces $1.2M Financing
6. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
7. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
8. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
9. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference